KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Change in Accured Expenses (2018 - 2025)

Esperion Therapeutics' Change in Accured Expenses history spans 8 years, with the latest figure at $12.7 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 100.41% year-over-year to $12.7 million; the TTM value through Dec 2025 reached $31.2 million, up 70.23%, while the annual FY2025 figure was $31.2 million, 70.23% up from the prior year.
  • Change in Accured Expenses reached $12.7 million in Q4 2025 per ESPR's latest filing, down from $21.2 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $25.0 million in Q1 2021 to a low of -$21.8 million in Q2 2021.
  • Average Change in Accured Expenses over 5 years is $4.1 million, with a median of $2.8 million recorded in 2021.
  • Peak YoY movement for Change in Accured Expenses: plummeted 394.93% in 2021, then surged 690.34% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at -$789000.0 in 2021, then surged by 255.77% to $1.2 million in 2022, then surged by 566.8% to $8.2 million in 2023, then fell by 22.55% to $6.3 million in 2024, then surged by 100.41% to $12.7 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Change in Accured Expenses are $12.7 million (Q4 2025), $21.2 million (Q3 2025), and -$1.7 million (Q2 2025).